Andre Buret

Andre Buret IPC

Current positions:
Associate Vice-President Research, University of Calgary
Professor (with tenure), Biological sciences (Science)
Adjunct Professor, Physiology and Pharmacology (Medicine)
Vice-President (research), co-founder, Antibe Therapeutics
Director, NSERC CREATE Host Parasite Interactions
Vice-President; World Chito-Ryu Karate Association

Education / Training:
-Teaching Diploma, 1977 Neuchatel (Switzerland)
-Physical Education Certificate, 1983 Neuchatel (Switzerland)
-Licence es Science (Biology), 1983 Neuchatel (Switzerland)
-M.Sc., Parasitology, 1988 Calgary Canada
-Ph.D, Pathophysiology, 1991 Calgary Canada
-Post-doctoral fellowship, Mucosal Immunology, 1991-4 Newcastle Australia
-Post-doctoral fellowship, Gastroenterology 1994-5 Calgary

Diseases of the gastrointestinal tract and the lungs represent the most common cause of death in humans and other animal species worldwide. Using bacterial and parasitic models, the overall aim of Dr. Buret’s research is to characterize microbial-host interactions in these systems, and how such interactions may affect gastrointestinal and pulmonary physiology, responsiveness, inflammation, and chronic disease, in an attempt to develop novel therapeutic strategies, that may involve dietary modulation. Particular emphasis is given to the role of microbes in Inflammatory Bowel Diseases, and immunomodulation by antibiotics.

Dr. Buret established his research program at the University of Calgary in 1995. Dr. Buret has published over 140 peer-reviewed articles, 15 book chapters, and has been invited to deliver over 250 presentations worldwide. Dr. Buret holds over 20 issued patents, and contributed to the creation of three biotech spin-off companies. He has mentored, as principal supervisor, more than 60 undergraduate research projects, and trained over 30 Ph.D and M.Sc. students (all Research-based), as well as 12 post-doctoral fellows (and more than 70 other graduate students as co-supervisor), who have obtained positions in industry, academia, and government. He serves on many National, and International grant and government committees, and acts as advisor and/or board member for several institutes and private companies.

Dr. Buret was inducted in the Order of the University of Calgary (2013), a Fellow of the Royal Society of Tropical Medicine and Hygiene (London UK, 2001), and a Fellow of the American Gastroenterological Association (2009). His many awards include Graduate and Undergraduate Teaching Excellence awards from 2 universities, the 2007 NSERC Synergy Award for collaborative research and innovation from the Natural Sciences and Engineering Research Council of Canada, the 2007 Research Excellence Award from the Canadian Association of Gastroenterologists (for which he served as VP Research), the 2008 Robert A. Wardle Medal from the Canadian Society of Zoologists (Parasitology research), and a Killam Professorship (2012). He also was awarded the 2012 City of Calgary Booster Club Award for Athletic Leadership (in karate). His research has been funded by more than 70 grants from numerous organizations, including CIHR and NSERC, for a total of over $18 millions in operating research grants alone. Dr. Buret currently has an h index of 53 (Google scholar). Dr. Buret is a certified ski instructor, and he achieved the rank of go dan renshi (5th degree, international Expert Master certification) in Chito Ryu Karate.

Selected publications:

  1. BEATTY, JK, AKIERMAN, SV, MOTTA, JP, MUISE, S, BHARGAVA, A, BECK, PL, RIOUX, KP, MCKNIGHT, GW, WALLACE, JL, BURET, AG. (2016) Giardia duodenalis-induced dysbiosis of human intestinal microbiota biofilms. Int. J. Parasitol.  (in press)
  2. BURET, AG. (2016) Good bugs, Bad bugs in gut biofilms: The role of microbiota dysbiosis in chronic gastrointestinal consequences of infection. Am. J. Gastroenterol. 3:25-32 doi:10.1038/ajgsup.2016.11
  3. HALLIEZ, M., MOTTA, JP., FEENER, T., GUERIN, G., LEGOFF, L., FRANCOIS, A., COLASSE, E., FAVENNEC, L., GARGALA, G., LAPOINTE, T., ALTIER, C. BURET, AG. (2016) Giardia duodenalis induces bacterial translocation and causes post-infectious visceral hypersensitivity. Am J Physiol (Gastrointestinal and Liver Physiology) 310(8): G574-G585 DOI: 10.1152/ajpgi.00144.2015
  4. RETI, KL, TYMENSEN, LD, DAVIS, SP, AMREIN, MW, BURET, AG. (2015) Campylobacter jejuni increases flagellar expression and adhesion of non-invasive Escherichia coli: Effects on enterocytic TLR-4 and CXCL-8 expression. Infection and Immunity 83(12):4571-4581 doi:10.1128/IAI.00970-15       
  5. GERBABA, T, GUPTA, P, RIOUX, K, HANSEN, D, BURET, A.G. (2015) Giardia duodenalis –induced alterations of commensal bacteria are toxic to Caenorhabditis elegans: a new model to study microbial-microbial interactions in the gut. Am. J. Physiol (Gastrointestinal Liver Physiol). 308: 550-561   doi:10.1152/ajpgi.00335.2014.
  6. DUQUETTE SC, FISCHER CD, WILLIAM AC, SAJEDY S, RETI K, FEENER TD, MUENCH GP, MORCK DW, ALLISON J, LUCAS MJ, BURET AG. (2015)Immunomodulation by Antibiotics: Tulathromycin Promotes Porcine Neutrophil Apoptosis, Enhances Efferocytosis and Inhibits Pro-inflammatory Leukotriene B4 Production in Actinobacillus pleuropneumoniae- and Zymosan-challenged Piglets. AM. J. VET. RES 76(6):507-519
  7. MOTTA JP, FLANNIGAN, K, AGBOR, T, BEATTY, J, BLACKLER, R, WORKENTINE, M, DA SILVA, G, WANG, R, BURET, AG*, WALLACE JL* (* equal contributions). (2015) Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production. Infl. Bowel Dis. 21(5): 1006-1017.
  8. COTTON J, MOTTA JP, SCHENK LP, HIROTA, SA, BECK PL, BURET, AG (2014). Giardia duodenalis infection reduces granulocyte infiltration in an in vivo model of bacterial toxin-induced colitis and attenuates inflammation in human intestinal tissue. PLoS ONE; 9(10): e109087
  9. FISCHER, CD, DUQUETTE, SC, RENAUX, BS, FEENER, TD, MORCK, DW, HOLLENBERG, MD, LUCAS, MJ, BURET, AG. (2014) Tulathromycin exerts proresolving effects in bovine neutrophils by inhibiting phospholipases and altering Leukotriene B4, Prostaglandin E2, and Lipoxin A4 production. Antimicrob. Ag. Chemother. 58(8):4298-4307.